| Trial ID: | L0903 |
| Source ID: | NCT01594424
|
| Associated Drug: |
Tocilizumab
|
| Title: |
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01594424/results
|
| Conditions: |
End Stage Renal Disease (ESRD)
|
| Interventions: |
DRUG: Tocilizumab|DRUG: Intravenous Immunoglobulin
|
| Outcome Measures: |
Primary: Number of Participants With Serious Infectious Complications Following Transplantation, patients will be in the study for up to 2 years, 24 months |
|
| Sponsor/Collaborators: |
Sponsor: Cedars-Sinai Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-06
|
| Completion Date: |
2015-05
|
| Results First Posted: |
2015-08-05
|
| Last Update Posted: |
2016-08-25
|
| Locations: |
Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01594424
|
